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THE ESTIMATION POWER OF ALTERNATIVE COMORBIDITY
INDEXES
Baser O1, Stephenson J2
1Thomson-Medstat, Ann Arbor, MI, USA, 2Thomson Medstat,
Philadelphia, PA, USA
OBJECTIVES: Health care expenditures are strongly inﬂuenced
by overall illness burden. Appropriate risk adjustment is required
for correct policy analysis. We compared three risk adjustment
methods—Charlson Comorbidity Index (CCI), Elixhauser
(ELX), and Chronic Disease Score (CDS)—in terms of their 
estimation power in analyses of healthcare expenditures.
METHODS: Seven models were considered. Using the same
demographic factors, models were separated by index variables:
1) CHS only; 2) ELX only; 3) CDS only; 4) CHS and ELX; 5)
CHS and CDS; 6) CDS and ELX; and 7) CHS, ELX, and CDS.
A generalized linear model with log link and gamma family was
used to estimate the models. BIC, AIC, and log likelihood scores
were calculated across the models to see which model afforded
the best ﬁt. Average squared prediction error (ASPE) was con-
sidered to asses the estimation power of these indexes.
RESULTS: MarketScan® data were used to estimate the total
health care expenditures of migraine patients treated with a
triptan. After applying inclusion and exclusion criteria, we iden-
tiﬁed 43,776 migraine patients who used a triptan and we used
this population to create the analytic samples. CCI, an older and
common risk adjustment method, performed the poorest in
terms of estimation power. Of the single-index models (models
1–3), ELX performed the best; of the double-index models
(models 4–7), CCI and ELX performed the best. We conducted
a detailed analysis of multicollinearity using a variance inﬂation
factor and failed to ﬁnd any multicollinearity among the three
measures. Overall, model 7, where we used three indexes in the
same model, performed the best. CONCLUSION: We found that
the three risk adjustment indexes measure different risks and that
the indexes can be used together in a single model. Using only
CCI is misleading.
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FAILURE OF REGRESSION ADJUSTMENT AGAINST
PROPENSITY SCORE MATCHING
Baser O
Thomson-Medstat, Ann Arbor, MI, USA
OBJECTIVES: Causal inference is challenging in observational
studies because of inevitable presence of self-selection: treatment
group are usually different from control group in terms of risk
factors. Regression adjustment and propensity score matching
are commonly used methods to adjust for confounders. In this
paper, we show when regression adjustment fails to adjust for
differences in observed covariates and propensity score match-
ing is the only alternative. METHODS: The following guidelines
are provided to decide which method should be used. Multi-
variate analysis fails if 1) the distributions of the covariates in
both groups are not symmetric; 2) the sample sizes are different;
3) the distributions of the covariates in both groups have differ-
ent variance and the means of propensity scores in the two
groups are more than half a standard deviation apart; 4) the ratio
of the variances of the propensity score in the two groups differs
from one; or 5) the ratio of the variances after residuals of the
covariates (including propensity score) is different from one.
RESULTS: To apply the suggested guidelines, we conducted a
retrospective cohort study analyzing the impact of triptan use on
total healthcare expenditures among patients with migraine.
Medstat MarketScan® data were used for the analysis. We
applied the suggested guidelines, and found that propensity score
matching, rather than multivariate analysis, should be used to
estimate treatment effect. The means of propensity score were
two standard deviations apart, the Smirnow test showed that the
distributions were not symmetric (p = 0.0000), sample sizes were
different (treatment = 43,799 vs. control = 128,366), and boot-
strapping results showed that the ratio of variance of the propen-
sity score in the two groups and in residuals were signiﬁcantly
different from one. CONCLUSIONS: Results from regression
analysis can be misleading and propensity score matching should
be used as an alternative under certain conditions.
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EXTENDING MATCHING ESTIMATORS OF CAUSAL EFFECTS
TO CONSIDER UNOBSERVED VARIABLE BIAS: AN
APPLICATION OF SENSITIVITY ANALYSIS
Devine JW, Hadsall RS, Farley JF
University of Minnesota, Minneapolis, MN, USA
OBJECTIVES: Unobserved variable bias remains a major limi-
tation of observational studies that rely on matching estimators
to examine causal effects. Several methods have been proposed
to quantify the extent of uncertainty about unobserved variable
bias. The primary aim of this study was to illustrate Rosen-
baum’s method of sensitivity analysis to examine how inferences
from observational research may change in the presence of
varying amounts of unobserved variable bias. METHODS: Data
used in the illustration were collected from an administrative
claims database as part of an observational study that evaluated
the effect of daily migraine prevention on the consumption of
migraine-speciﬁc abortive medication. The database included
information on all prescription services rendered between 1
October 2002 and 30 September 2004 for a population of
migaineurs in the Military Health System. Each patient receiv-
ing treatment (daily migraine prevention) during the observation
period was matched to a similar untreated patient via nearest
neighbor matching on a propensity score. The illustration of the
sensitivity analysis was based on the Wilcoxon’s signed rank sta-
tistic and attempted to estimate the magnitude of departure from
equal treatment probabilities between matched pairs sufﬁcient to
alter the statistical conclusions of the study results. RESULTS:
The analysis of 997 matched pairs suggested that treatment with
daily migraine prevention was associated with a decline in the
use of migraine-speciﬁc abortive medication. However, the sen-
sitivity analysis indicated that the treatment effects were sensi-
tive to assumptions about unobserved variable bias. Speciﬁcally,
the probability of obtaining the results under the null hypothe-
sis of no effect approached the conventional 0.05 level when the
odds of receiving treatment within matched pairs differed by a
factor of 1.4 or more. CONCLUSIONS: Rosenbaum’s sensitiv-
ity analysis is a useful mechanism for discussing the magnitude





THE EFFECT OF ADHERENCE TO ALZHEIMER’S DISEASE
TREATMENT ON HEALTH CARE COSTS IN MANAGED CARE
Harada ASM,Vanderplas AM
Prescription Solutions, Irvine, CA, USA
OBJECTIVE: To determine the effect of Alzheimer’s disease
(AD) treatment adherence on the change in overall health care
costs following AD treatment initiation in managed care.
METHODS: A retrospective analysis was conducted using phar-
macy, medical, and member eligibility data from a large managed
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care organization. Members initiating therapy between January
1, 2004 and June 30, 2004 with one of the following ﬁve AD
regimens were included in the analysis: donepezil, galantamine,
rivastigmine, memantine, or memantine+AChEI (acetyl-
cholinesterase inhibitor) combination. We excluded members
with previous AChEI use or who were not continuously enrolled
throughout the 360-day pre-treatment and 360-day post-treat-
ment initiation periods. Adherence was deﬁned as the total days
supplied (maximum of 360) of the AD medication initiated
divided by the total days in the post-period (360 days). Change
(post-treatment minus pre-treatment) in pharmacy, medical, and
total (pharmacy+medical) costs was analyzed, adjusting for age,
gender, comorbidities (chronic disease score), AD regimen, and
pre-treatment total costs. RESULTS: A total of 2405 members
were newly started on AD therapy; 65% were female and mean
age was 81 years (SD 7.1). Treatment was initiated with
donepezil (62%), memantine (15%), galantamine (11%),
rivastigmine (8%), and memantine+AChEI (6%). Mean adher-
ence to AD therapy was 0.57 (SD 0.36). The adjusted analysis
revealed that a 0.1 adherence rate increase (for example, an
increase in adherence from 0.5 to 0.6) was associated with an
increase of $215 (p < 0.001) in annual pharmacy costs and a
decrease of $783 (p < 0.001) and $568 (p = 0.008) in annual
medical and total health care costs, respectively. CONCLU-
SIONS: An increase in AD therapy adherence is associated with




AUGMENTATION USING COMPETING RISK METHODS
Gause D,Arcona S
Novartis Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVES: To illustrate use of competing risk methodology
for studying risk of discontinuing, switching, or augmenting
medications used to treat bipolar disorders. METHODS: Admin-
istrative claims data (MarketScan®, Medstat) was used to iden-
tify patients with bipolar disorders treated with montherapy
atypical antipsychotics. Patients were followed 12 months to
identify those augmenting (starting second medication class
within 30 days and before any discontinuation), discontinuing
(medications runs out and no reﬁll within 30 days following
expiration of days supply), and switching (patient discontinues
medications and starts different class within 30 days). Because
risks of augmentation, discontinuation, and switching are not
independent, competing risk methods are used to summarize
likelihood of different outcomes. Cumulative incidence functions
are computed as a function of crude hazards for each of the 3
dependent outcomes. Plots of the cumulative incidence functions
provide estimates of the probability of each outcome occurr-
ing by any time point. RESULTS: A total of 787 patients on
monotherapy atypical antipsychotics were identiﬁed. By 6
months 21% of the patients had discontinued, 3% had switched,
56% had augmented, and the remaining 20% remained on their
initial antipsychotic. By one year 29% of the patients had dis-
continued, 4% had switched, 59% had augmented, and 8%
remained unchanged. CONCLUSIONS: Switching and augmen-
tation are outcomes important to study along with discontinua-
tion. Treating these as independent when estimating risk of each
(e.g. with complement of Kaplan-Meier estimates) would give
biased estimates of the marginal probabilities. Cumulative inci-
dence curves provide a means of dynamically seeing the risks of
all three outcomes.
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A REVIEW OF THE VALIDITY AND RELIABILITY OF THE
PARKINSON’S DISEASE QUESTIONNAIRE (PDQ-39)
Stafkey-Mailey DR1, Gwadry-Sridhar F2
1University of Southern California, Los Angeles, CA, USA, 2University
of Western Ontario, and London Health Sciences Centre, London,
ON, Canada
OBJECTIVE: Patients with Parkinson’s Disease (PD) have
diminished health related quality of life (HRQoL) due to a
number of emotional, functional and physical limitations. We
examined the reliability and validity of the PDQ-39 as both a
discriminant and evaluative instrument for use in Parkinson’s
disease studies. METHODS: We conducted a literature review
using MEDLINE and HealthStar citing the PDQ-39, from
1995–2005 using the terms “Parkinson’s Disease Questionnaire
or PDQ-39” limited to Humans and English language. We
reviewed each publication for evidence supporting the instru-
ment’s reliability face and content validity, construct validity
measured as the correlation of the PDQ-39 responses with other
relevant instruments and clinical measures, and test-retest relia-
bility or intra class correlation coefﬁcients. Discriminant abilities
were evaluated by looking for evidence of signiﬁcance between
PD patients with varying levels of disability. Responsiveness was
evaluated using change scores and established minimally impor-
tant difference (MID). RESULTS: Thirty-nine papers met the
inclusion criteria. Correlation of scales of the PDQ-39 with the
Medical Outcomes Study 36-item Short Form (SF-36) showed
strong correlation (>0.5). Intraclass correlation coefﬁcients for
each domain of the PDQ-39 ranged from 0.67 to 0.96 across
studies. Mean scores for each domain were shown to be signiﬁ-
cantly statistically different (p < 0.01) between PD patients with
Hoehn & Yahr rating I, II, III, and IV. Changes in PDQ-39 scores
were signiﬁcantly correlated with changes in patients’ retrospec-
tive judgments of change (0.25–0.31, p < 0.01), and changes on
the SF-36 (0.25–0.37, p < 0.05), but not with clinical assess-
ments. Two studies calculated a MID for the PDQ-39 which
varied between 5–10 points on the summary index and 2–11
points across domains. CONCLUSION: There is substantial evi-
dence supporting the reliability and validity of the PDQ-39 as a
discriminate instrument, but further research on its usefulness as
an evaluative instrument is warranted to increase our conﬁdence.
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COMPARISON OF HEALTH-RELATED QUALITY OF LIFE
QUESTIONNAIRES IN MULTIPLE SCLEROSIS: A REVIEW
Pawar VS, Miller LA
West Virginia University, Morgantown, WV, USA
Multiple sclerosis (MS) being a progressive neurological disease
with no cure, lends itself as an important area for health-related
quality of life (HRQOL) research. A number of questionnaires
have been designed to measure HRQOL in MS patients, but no
one measure has been established as a gold standard. The large
number of questionnaires also gives neurologists a range of
choices but limited information on which to base their selection.
In order to determine the relative advantages and disadvantages
of the HRQOL questionnaires, a comparison of their psycho-
metric properties in the same patient population is necessary.
OBJECTIVE: To review the current literature and identify
studies comparing psychometric properties of MS-related QOL
measures within the same patient population. METHODS:
Studies included were those that administered more than one
HRQOL questionnaire in the same group of patients with MS.
The search was restricted to the PUBMED and MEDLINE data-
bases for articles published between 1991 and 2005. RESULTS:
Of almost 30 MS-related QOL questionnaires, psychometric
